US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.78 against a street estimate of 0.34 — a beat of 129.4%.
Analysts rate Supernus Pharmaceuticals Inc a strong buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $60.50.
CONFIDENT Supernus delivered record third-quarter revenue, raised standalone 2026 guidance, and reported strong growth across Qelbree, Zurzuvae, Onapco, and Gocovri ahead of its expected Indivior merger closing. Q3 FY26 Analysts focused on Zurzuvae commercialization, M&A priorities and synergies, Onapco enrollment momentum, Qelbree trends, margins, and pipeline timing. Management emphasized strong brand demand, integration execution, and continued business development. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.06% |
| Millennium Management LLC | 6.62% |
| Vanguard Portfolio Management, LLC | 5.68% |
| Armistice Capital, LLC | 4.54% |
| Vanguard Capital Management, LLC | 4.32% |
| State Street Corp | 4.22% |
| Delaware Management Holdings Inc | 4.08% |
| Dimensional Fund Advisors, Inc. | 3.57% |
| Document | Date |
|---|---|
| Company announcement · Q4 2026 HEADLINE NUMBERS • Supernus increased the conversion rate on its 0.625% Convertible Senior Notes due 2031 from 24.0033 shares to 30.9355 shares per $ | 2026-11-03 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • On November 2, 2026, Indivior Pharmaceuticals completed its merger with Supernus Pharmaceuticals. • Indivior was renamed Supernus | 2026-11-02 |
| Current report · Q4 2026 HEADLINE NUMBERS • Supernus Pharmaceuticals reported that its merger was completed on November 2, 2026. • The company notified Nasdaq that trading i | 2026-11-02 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • On November 2, 2026, Supernus Pharmaceuticals completed its merger with Indivior Pharmaceuticals. • Supernus became a wholly owne | 2026-11-02 |
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 net revenue was $356 million, up from $314 million in third-quarter 2025. Nine-month revenue was $1,016 million | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total net revenue was $356 million, up 13% year over year from $314 million. • Q3 2026 net income was $137 million, or $1 | 2026-10-29 |
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $226.771 million, up from $192.103 million in the third quarter of 2025. • Third-quarter 2026 net | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue reached a record $226.8 million, up 18% from $192.1 million in Q3 2025. • Nine-month 2026 revenue was $653.5 mill | 2026-10-29 |
Readable in the app.
| Announcement | Date |
|---|---|
| Special cash dividend declared contingent on Supernus merger closing Indivior Pharmaceuticals announced a special cash dividend of $8.13 per share, contingent on closing its merger with Supernus Pharmaceuticals expected around November 2, 2026. The dividend w | 2026-09-17 |
| Entered into merger agreement with Supernus Pharmaceuticals Indivior Pharmaceuticals announced on August 1, 2026 that it has agreed to merge with Supernus Pharmaceuticals in an all-stock transaction. Under the merger agreement, each Supernus share wi | 2026-08-03 |
| Agreement and Plan of Merger executed with Supernus Pharmaceuticals Indivior Pharmaceuticals announced on August 3, 2026, that it has signed a merger agreement to acquire Supernus Pharmaceuticals. The companies executed the Agreement and Plan of Merger dated | 2026-08-03 |
| Accelerated share repurchase agreement for $175 million announced Indivior Pharmaceuticals announced on May 4, 2026, that it entered into an accelerated share repurchase (ASR) agreement with an investment bank to buy back $175 million of its own stock. Thi | 2026-05-04 |
| Financial guidance for 2026 announced with updated corporate presentation Indivior PLC, a pharmaceutical company trading on NASDAQ under ticker INDV, filed an 8-K on January 8, 2026 to disclose the issuance of a press release and updated corporate presentation ann | 2026-01-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Supernus Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.